“炎-癌转化”型结直肠癌药物治疗靶标的研究进展  

Advances on therapeutic targets for colitis-associated cancer

作　　者：林倩文 汪哲 余嘉莉 刘碧珊[2] 谭宁华[1] Lin Qianwen;Wang Zhe;Yu Jiali;Liu Bishan;Tan Ninghua(School of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing,Jiangsu 211198,China;Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants,The Chinese University of Hong Kong,Hong Kong 999077,China)

机构地区：[1]中国药科大学中药学院,江苏南京211198 [2]香港中文大学中医中药研究所及药用植物应用研究国家重点实验室,香港999077

出　　处：《医药前沿》2020年第21期5-7,共3页Journal of Frontiers of Medicine

基　　金：国家新药科技重大专项课题(2017ZX09309027).

摘　　要：结直肠癌是发生于结肠和直肠的肿瘤统称。近年来,随着人们生活方式的转变和饮食的西化,我国结直肠癌发病率逐年升高。“炎-癌转化”是慢性炎症转化为癌症的过程。炎症型结直肠癌的生物特征不同于散发性结直肠癌,持续的肠道炎症是导致“炎-癌转化”的主要因素。本文综述了结肠炎相关结直肠癌的发展以及近年来的相关药物靶标研究,为结直肠癌防治和预后提供参考。Colorectal cancer is a tumor that occurs in the colon and rectum.In recent years,with the transformation of the people's life style and the westernization of the diet,the incidence of colorectal cancer was increased year by year.“Inflammation-cancer transformation”is the process of transforming chronic inflammation into cancer.The biological characteristics of the inflammatory colorectal cancer are different from the sporadic colorectal cancer,and the persistent intestinal inflammation is a major factor leading to the“inflammation-cancer transformation”.In this paper,the development of colitis-associated cancer and the related drug targets in recent years were reviewed,which provided ideas for the prevention,treatment and prognosis of colorectal cancer.

关 键 词：炎-癌转化 肠道炎症 结肠炎相关结直肠癌 靶向治疗 药物靶标 

分 类 号：R735.34[医药卫生—肿瘤]